Elena Ridloff, Director at Kymera Therapeutics, Inc. (KYMR), sold 12,000 shares at $85.37 ($1.0M) on 2026-03-31, disclosed to the SEC on 2026-04-01.
Scheduled sale ($1.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $85.37 | 7,400 | $632K | 61.7% |
| 2 | $85.19 | 3,400 | $290K | 28.3% |
| 3 | $86.05 | 1,200 | $103K | 10.1% |
| Total | $85.39 avg | 12,000 | $1.0M | 100% |
| Filing → |
| SION | SELL | 2025-08-28 | $1.1M | — | Filing → |
| SION | SELL | 2025-08-21 | $1.9M | — | Filing → |
| KYMR | SELL | 2025-06-11 | $225K | — | Filing → |